“We’re not just developing another drug, we’re striving to pioneer a new era of brain-first recovery that could transform how we treat neurological trauma,” said Janet Huffman, Chief Executive Officer of Oragenics (OGEN). “We believe that our proprietary nasal delivery platform and our lead candidate ONP-002 for concussion, the Company’s current cash position, combined with strategic partnerships, position us to lead a paradigm shift in neurotrauma care. We believe that early treatment could prevent chronic brain disorders as a result of mTBI.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGEN:
- Oragenics selects South Star Research as its CRO for ONP-002 Phase IIa trial
- Oragenics announces manufacturing agreement with Sterling Pharma for ONP-002
- Oragenics Raises $16.5M Through Public Offering
- Why Is Oragenics Stock (OGEN) Down 55% Today?
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!